$1.52 Billion is the total value of Novo Holdings A/S's 47 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CTLT | Sell | CATALENT INC | $54,728,413 | -25.5% | 832,878 | -49.0% | 3.61% | -21.3% |
| AAPL | Sell | APPLE INC | $48,691,672 | +1.5% | 295,280 | -20.0% | 3.21% | +7.3% |
| Sell | ARCELLX, INC. | $37,742,250 | -17.9% | 1,225,000 | -17.5% | 2.49% | -13.2% | |
| SGEN | Sell | SEAGEN INC. | $27,330,615 | +1.3% | 134,986 | -35.7% | 1.80% | +7.0% |
| INSP | Sell | INSPIRE MED SYS INC | $14,044,200 | -11.9% | 60,000 | -5.2% | 0.93% | -6.9% |
| TMCI | Sell | TREACE MED CONCEPTS INC | $13,602,600 | -7.2% | 540,000 | -15.3% | 0.90% | -2.0% |
| Sell | RALLYBIO CORP | $12,962,328 | -14.1% | 2,270,110 | -1.1% | 0.86% | -9.2% | |
| NARI | Sell | INARI MED INC | $11,113,200 | -27.4% | 180,000 | -25.2% | 0.73% | -23.3% |
| LVTX | Sell | LAVA THERAPEUTICS NV | $5,097,126 | -56.2% | 3,070,558 | -7.7% | 0.34% | -53.8% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $1,457,341 | -82.4% | 465,604 | -60.4% | 0.10% | -81.4% |
| BSX | Exit | BOSTON SCIENTIFIC CORP | $0 | – | -1,353,081 | -100.0% | -3.91% | – |
| STE | Exit | STERIS PLC | $0 | – | -467,687 | -100.0% | -5.39% | – |
| SYK | Exit | STRYKER CORPORATION | $0 | – | -796,941 | -100.0% | -12.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
| SC 13D/A | 2024-03-07 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.